Childs, Alexa
Zakeri, Nekisa
Ma, Yuk Ting
O’Rourke, Joanne
Ross, Paul
Hashem, Essam
Hubner, Richard A.
Hockenhull, Kimberley
Iwuji, Chinenye
Khan, Sam
Palmer, Daniel H.
Connor, Joanna
Swinson, Daniel
Darby, Suzanne
Braconi, Chiara
Roques, Tom
Yu, Dominic
Luong, Tu Vinh
Meyer, Tim http://orcid.org/0000-0003-0782-8647
Article History
Received: 11 June 2021
Revised: 4 August 2021
Accepted: 20 August 2021
First Online: 15 September 2021
Ethics approval and consent to participate
: This study was classified as a national audit and clinical evaluation by the Caldecott Guardian, the primary aim of which was to evaluate the feasibility, safety and outcome of diagnostic liver biopsy. As such individual patient consent was not required.
: TM has served as a consultant for Eisai, Ipsen, Astra Zeneca, Roche, Boston Scientific and Bayer. The other authors declare no competing interests.
: TM was partly funded by the NIHR UCLH Biomedical Research Centre and Cancer Research UK (CR UK) Accelerator award C9380/A26813.